Treatment of MCF-7 and MDA-MB468 breast cancer cells with BAY 73–6691 led to a dose- and time-dependent reduction in cell proliferation and an increase in apoptosis, highlighting PDE9A as a promising therapeutic target in breast cancer (Table 1) (79). Here, PDE9A is linked to breast carcinoma.